A multicenter prospective cohort study of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma
Latest Information Update: 29 Jul 2021
At a glance
- Drugs Anti-CTLA-4 monoclonal antibody (Primary) ; Cobimetinib (Primary) ; Dabrafenib (Primary) ; Programmed cell death-1 ligand-1 inhibitors (Primary) ; Trametinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms MELBASE
- 29 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology